Valuation: Mylan N.V.

Market Cap 19.73B 17.32B 16.28B 14.88B 27.81B 1,890B 28.02B 196B 75.81B 964B 74.1B 72.48B 3,125B P/E 2026 *
73.9x
P/E 2027 * 42.3x
Enterprise Value 31.68B 27.81B 26.14B 23.9B 44.66B 3,035B 44.99B 314B 122B 1,547B 119B 116B 5,017B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 2.02x
Free-Float
91.44%
Yield 2026 *
2.96%
Yield 2027 * 3.04%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 19.73B
-1.44%+1.75%+55.00%+109.63% 1,043B
-0.18%+0.58%+52.24%+67.74% 649B
+0.15%+0.96%+19.06%+71.37% 469B
-0.25%+0.19%+36.95%+45.54% 355B
+0.98%+2.91%+20.59%+27.14% 270B
-1.91%+2.42%+10.41%+11.04% 262B
-0.97%+8.50%+42.38%+53.02% 222B
-0.92%+1.83%+31.45%+100.96% 189B
-2.53%-7.47%-32.63%-60.41% 175B
Average -0.45%+2.20%+26.16%+47.34% 403.67B
Weighted average by Cap. -0.66%+2.19%+36.11%+65.62%

Financials

2026 *2027 *
Net sales 14.79B 12.98B 12.2B 11.16B 20.85B 1,417B 21B 147B 56.82B 722B 55.54B 54.32B 2,342B 15.04B 13.2B 12.41B 11.34B 21.2B 1,440B 21.35B 149B 57.77B 734B 56.47B 55.23B 2,381B
Net income 142M 124M 117M 107M 199M 13.56B 201M 1.4B 544M 6.91B 531M 520M 22.41B 298M 262M 246M 225M 421M 28.58B 424M 2.96B 1.15B 14.57B 1.12B 1.1B 47.25B
Net Debt 11.95B 10.49B 9.86B 9.01B 16.85B 1,145B 16.97B 118B 45.91B 584B 44.88B 43.9B 1,892B 10.68B 9.38B 8.82B 8.06B 15.06B 1,023B 15.17B 106B 41.05B 522B 40.12B 39.24B 1,692B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!